Quantcast

Latest Peptides Stories

2009-10-05 07:30:00

BASKING RIDGE, N.J., Oct. 5 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the Japan Biopharma Conference 2009 at the Conrad Hotel in Tokyo, Japan. Dr. Mazzo's presentation is scheduled for 2:40pm (GMT +9:00) on October 6, 2009. The Conference brings together premier biotechnology companies...

2009-10-04 15:00:11

Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately "“ because the blood thinner and antidote were designed to work together. Researchers at Duke University Medical Center have engineered a way to do this for an entire, versatile class of drugs called aptamers and published their findings in Nature Medicine. "With any anticoagulant, you are trying to reduce your chances of having clotting because it can lead...

2009-09-17 19:54:00

BASKING RIDGE, N.J., Sept. 17 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the European Patent Office (EPO) has notified the Company of its intent to grant a patent with claims directed to oligonucleotide modulators of blood coagulation factor aptamers in EP 1401853. This new patent grant in the Company's portfolio extends the scope and breadth of Regado's intellectual...

2009-09-15 15:05:00

PALO ALTO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in New York City on Tuesday, September 22, 2009 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on...

2009-09-09 11:35:00

MATTHEWS, N.C., Sept. 9 /PRNewswire/ -- CEM Corporation, a leading global provider of microwave laboratory instrumentation, is pleased to announce that its fourth US patent covering microwave-assisted peptide synthesis (US 7,582,728) was issued on September 1, 2009. The patent contains broad claims regarding the process of using microwave energy to accelerate two key steps in performing almost all solid phase peptide synthesis, deprotection and coupling. In addition, the Company's third...

2009-09-04 07:30:00

BASKING RIDGE, N.J., Sept. 4 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the Thomas Weisel Partners Healthcare Conference 2009 in Boston, MA at 9:45 AM on Friday, September 11, 2009 (EDT). Ms. McDonald's presentation will include an overview of the Company's pipeline with emphasis...

2009-09-03 07:30:00

BASKING RIDGE, N.J., Sept. 3 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 11th Annual Healthcare Conference of the Rodman & Renshaw Global Investment Conference in New York, NY at 4:30 PM on Thursday, September 10, 2009 (EDT). Dr. Mazzo's presentation will include an overview of the...

2009-08-31 07:30:00

BASKING RIDGE, N.J., Aug. 31 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the results of a Phase 2a clinical trial of their lead product, the anticoagulant system REG1, were released at the European Society of Cardiology Congress in Barcelona, Spain. The results, detailed in a poster entitled, "First Clinical Application of an Actively Reversible Direct Acting Factor IXa...

09548f6943a1ea96fb10913a48d7b614
2009-08-06 11:04:38

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and "“ ideally "“ its effects will be reversible, to cut short any potentially dangerous side effects.University of Illinois researchers report that they have assembled a new cancer drug delivery system that, in cell culture, achieves all of the above. The findings appear this month in the journal Angewandte Chemie.The team began with the...

2009-08-05 14:04:55

A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases, as described in a comprehensive review article published online ahead of print in Oligonucleotides, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/oliAptamers offer...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related